ONGITUDINAL FOLLOW-UP OF SARS-COV-2 (COVID-19) IMMUNITY IN IMMUNOCOMPROMISED POPULATIONS IN BELGIUM (COVICO)A non-commercial multicenter academic prospective cohort study during 2023-2026
Phase 1
- Conditions
- Healthy persons and immunocompromised patients (nursing home residents, dialysis patients and kidney- and lung transplant patients) from age 18 till age 105Therapeutic area: Body processes [G] - Immune system processes [G12]
- Registration Number
- EUCTR2022-002531-56-BE
- Lead Sponsor
- Sciensano
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- 360
Inclusion Criteria
•Having participated in the previously organized PICOV-VAC, REDU-VAC, Lung-VAC or Nephro-VAC cohorts
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 200
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 160
Exclusion Criteria
-Having a previous diagnosis of dementia and/or having a mini-mental state examination (MMSE) score < 18/30.
-Having veins which are not accessible for simple peripheral blood puncture.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method